Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Cuts Price of Insulin in the Wake of the Coronavirus

By Eric Volkman – Apr 13, 2020 at 9:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is capping the price at $35 per month for most patients.

Eli Lilly (LLY 0.19%) is giving diabetes patients in the U.S. a break. The pharmaceutical giant is capping the out-of-pocket cost of most of its insulins to $35 per month to help ease the financial burden on diabetics who might be facing financial challenges due to the SARS-CoV-2 coronavirus outbreak.

This cap will apply to both patients who hold commercial health insurance and those who have no insurance coverage. Those covered under government insurance plans such as Medicaid and Medicare will not be eligible for the discounted price. 

Diabetes spelled out in small tiles and surrounded by syringes and pills.

Image source: Getty Images.

Perhaps not coincidentally, in March the government announced a plan under which insulin would be capped at $35 per month for people enrolled in Medicare.

In recent years, insulin manufacturers -- of which Eli Lilly is a major one -- have come under fire from consumer advocates because of the high price of the medicine. From 2012 to 2016 that cost nearly doubled. Under heavy criticism, those companies have recently started to cut prices.

Following a round of Senate hearings on the subject in early 2019 in which seven executives from pharmaceutical companies active in the insulin market were questioned by lawmakers, a round of reductions occurred. Although Eli Lilly did not participate in the Senate hearings, it nevertheless rolled out generic versions of its popular insulin Humalog that were priced more than 50% lower than the branded product.

On Thursday, Eli Lilly's shares fell marginally, while the broader stock market and most major equity indexes rose on the day.

 
None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$311.46 (0.19%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.